Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis

Area of Science:

• Stem cell biology
• Neuroscience
• Immunology

Background:

• Cellular reprogramming to generate induced pluripotent stem cells (iPSCs) offers novel avenues for studying complex diseases.
• Multiple Sclerosis (MS) is a debilitating neuroinflammatory disease characterized by demyelination and neuronal loss, posing significant modeling challenges.
• Patient-derived iPSCs provide a powerful platform for investigating disease mechanisms and testing therapeutics.

Purpose of the Study:

• To generate and characterize patient-specific induced pluripotent stem cell (iPSC) lines from individuals with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).
• To differentiate these MS iPSC lines into neural progenitor cells (NPCs) to model central nervous system pathology.
• To identify molecular mechanisms underlying MS pathogenesis using these cellular models, focusing on cellular senescence.

Main Methods:

• Generation of iPSC lines from peripheral blood mononuclear cells (PBMCs) of RRMS and PPMS patients and healthy controls.
• Characterization of iPSC pluripotency using embryonic stem cell (ESC) morphology and marker expression.
• Neural induction of iPSCs to differentiate them into neural progenitor cells (NPCs).
• Analysis of cellular senescence hallmarks in MS-derived NPCs.

Main Results:

• Successful generation of multiple patient-specific iPSC lines from RRMS and PPMS individuals.
• MS iPSC lines exhibited characteristic ESC morphology and pluripotency markers.
• Differentiation into NPCs was achieved, and elevated expression of cellular senescence hallmarks was observed in RRMS and PPMS NPCs.
• Identification of cellular senescence as a potential contributor to MS pathophysiology.

Conclusions:

• Generated RRMS and PPMS iPSC lines serve as valuable cellular models for Multiple Sclerosis research.
• These models facilitate a deeper understanding of MS pathologies and enable drug screening.
• The identification of cellular senescence in MS NPCs highlights a novel therapeutic target avenue for MS treatment.